AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
On August 11, 2025,
(MLNK) surged 24.56% with a trading volume of $0.30 billion, marking a 6,438% increase from the previous day and ranking 340th in market activity. The rally followed an announcement of its acquisition by Centerbridge Partners for $2.0 billion in an all-cash deal. Shareholders will receive $20.00 per share, a 26% premium over the closing price on August 8, 2025. The transaction, expected to close in the second half of 2025, requires shareholder approval and regulatory clearances. Upon completion, MeridianLink will delist from the NYSE and operate as a private entity, with its headquarters remaining in Irvine, California.The acquisition underscores Centerbridge’s confidence in MeridianLink’s digital lending platform, which serves nearly 2,000
. Larry Katz, the company’s incoming CEO, highlighted plans to accelerate innovation, leverage AI, and enhance customer experiences. Centerbridge, with $43 billion in assets, emphasized its track record in financial technology investments. The deal aligns with MeridianLink’s strategic shift to prioritize growth in a rapidly evolving sector, supported by Centerbridge’s expertise in scaling tech-driven financial services.The strategy of purchasing the top 500 stocks by daily trading volume and holding for one day generated a 166.71% return from 2022 to the present, outperforming the benchmark by 137.53%. This highlights the impact of liquidity concentration on short-term performance, particularly in volatile markets, where high-volume stocks often exhibit amplified price movements due to increased investor activity and market depth. The results reinforce the role of liquidity in driving momentum-based strategies, especially for securities with significant trading interest.

Market Watch column provides a thorough analysis of stock market fluctuations and expert ratings.

Dec.26 2025

Dec.26 2025

Dec.25 2025

Dec.24 2025

Dec.24 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet